Do it right. Do it better.

Beating cancer isn't easy. Neither is running a clinical trial. We need to do it right and do it better. 

At the Dana-Farber/Harvard Cancer Center, our investigators are renowned for cutting-edge and ground-breaking science. The ODQ brings that same innovative spirit to clinical research quality and operations. 

Let's move research forward. The fight against cancer is too important not to.

ODQ News & Updates

  • October 22, 2019 – PRMS

    Subsites are currently not receiving activation emails for amendments. A solution for this is in development. For now, please check OncPro to see if the submission is active.

  • October 21, 2019 – PRMS

    All communication emails relating to a specific trial will be sent to the staff listed in iRIS under Study Contact. At time of new submission, the Overall PI will default to be listed as a study contact. If the PI has...

  • October 20, 2019 – PRMS

    Sub-site study status is not automatically updated when the lead site submits a status change amendment in iRIS. Sub-site status may also be an issue for migrated studies where an NPA or add site submission was submitted...

Most Accessed Documents

  • Link
  • Link
  • Link
  • Link
  • Link